Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2024.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.
Clin Med Insights Oncol
December 2024
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA.
Locally advanced and metastatic urothelial cancer (la/mUC) is an aggressive disease with poor prognosis. Platinum-based chemotherapy has remained the first-line treatment for decades and until recently no other treatment options existed. Today, novel agents called antibody drug conjugates (ADCs), including enfortumab vedotin (EV) and sacituzumab govitecan (SG), have been approved for la/mUC offering patients treatment options following or instead of traditional chemotherapy.
View Article and Find Full Text PDFUnveiling the Immunological Mechanism Underlying a Cutaneous Adverse Reaction to Enfortumab Vedotin: A Case Report Based on the Lymphocyte Transformation Test.
J Investig Allergol Clin Immunol
December 2024
Allergology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
Cancer Med
November 2024
Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
Article Synopsis
- Enfortumab vedotin is an antibody-drug conjugate that has shown to improve overall survival in patients with advanced urothelial carcinoma compared to standard chemotherapy, leading to its global approval.
- The EV-203 study is a phase 2 trial that evaluated the drug's effectiveness and safety in 40 Chinese patients with previously treated advanced disease.
- Results showed a 37.5% objective response rate, a 72.5% disease control rate, and median progression-free survival of 4.7 months, with no new safety concerns reported.
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
J Clin Oncol
October 2024
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Article Synopsis
- The study investigates the effectiveness of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, in patients with unresectable recurrent/metastatic head and neck cancer (HNC) who have previously received other therapies.
- In a phase II trial involving 46 patients, the objective response rate (ORR) was 23.9%, with a disease control rate (DCR) of 56.5%, while median progression-free survival (PFS) and overall survival (OS) were 3.9 and 6.0 months, respectively.
- Adverse events were primarily alopecia, fatigue, and peripheral sensory neuropathy, with 34.8% of patients experiencing
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis.
Urol Oncol
November 2024
Scott Department of Urology, Baylor College of Medicine, Houston, TX; Michael E. DeBakey VA Medical Center, Houston, TX.
Metastatic urothelial carcinoma (muC) has historically had few effective therapeutic options. Recently, immune checkpoint inhibitors (ICIs), were introduced as therapeutic options for cisplatin-ineligible patients, however, direct head-to-head trials comparing these treatments are lacking. To address this gap, this study employs a Bayesian framework to indirectly compare the performance of ICIs as first-line agents for muC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!